Sigma Planning Corp Lowers Stock Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Sigma Planning Corp reduced its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 3.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,627 shares of the company’s stock after selling 1,901 shares during the quarter. Sigma Planning Corp’s holdings in Hims & Hers Health were worth $1,176,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Creative Planning lifted its position in shares of Hims & Hers Health by 18.1% in the third quarter. Creative Planning now owns 25,925 shares of the company’s stock worth $478,000 after buying an additional 3,979 shares in the last quarter. International Assets Investment Management LLC bought a new stake in Hims & Hers Health in the 3rd quarter worth approximately $6,790,000. Dakota Wealth Management purchased a new stake in shares of Hims & Hers Health during the 3rd quarter worth approximately $245,000. Diversify Advisory Services LLC boosted its position in shares of Hims & Hers Health by 14.9% during the 3rd quarter. Diversify Advisory Services LLC now owns 51,828 shares of the company’s stock valued at $955,000 after acquiring an additional 6,706 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. purchased a new position in shares of Hims & Hers Health in the third quarter valued at $604,000. Institutional investors own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on HIMS shares. BTIG Research started coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. Morgan Stanley cut shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and upped their target price for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. Deutsche Bank Aktiengesellschaft lifted their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Piper Sandler upped their price objective on Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research report on Monday, January 6th. Finally, Bank of America lifted their target price on Hims & Hers Health from $18.00 to $21.00 and gave the stock an “underperform” rating in a report on Thursday, February 20th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $28.53.

Hims & Hers Health Price Performance

HIMS stock opened at $51.37 on Tuesday. Hims & Hers Health, Inc. has a 12 month low of $9.67 and a 12 month high of $72.98. The firm’s 50-day moving average is $35.45 and its 200 day moving average is $26.08. The company has a market capitalization of $11.22 billion, a PE ratio of 116.75 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Soleil Boughton sold 268,932 shares of Hims & Hers Health stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the transaction, the insider now directly owns 169,803 shares of the company’s stock, valued at $4,712,033.25. This trade represents a 61.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Michael Chi sold 2,054 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $33.56, for a total value of $68,932.24. Following the sale, the insider now owns 184,947 shares of the company’s stock, valued at approximately $6,206,821.32. This represents a 1.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,080,275 shares of company stock valued at $37,247,354 in the last ninety days. Corporate insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.